Alterity Therapeutics Limited (ATHE)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alterity Therapeutics Limited (ATHE) trades at $3.71 with AI Score 58/100 (Hold). Alterity Therapeutics Limited is a biotechnology company focused on developing treatments for neurodegenerative diseases. Market cap: 34M, Sector: Healthcare.
Last analyzed: Mar 15, 2026ATHE stock analysis for 2026: Analysts have set a consensus price target of $11.00 for Alterity Therapeutics Limited, suggesting 196.1% upside from the current price of $3.71. The AI MoonshotScore is 58/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
Alterity Therapeutics Limited (ATHE) Healthcare & Pipeline Overview
Alterity Therapeutics Limited is a biotechnology firm specializing in the development of therapeutic drugs for neurodegenerative diseases, including Parkinson's and Alzheimer's. Their lead asset, ATH434, is in clinical development for Parkinson's, while PBT2 targets Alzheimer's, positioning them in a high-need segment of the healthcare sector.
What Is the Investment Thesis for ATHE?
Alterity Therapeutics presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The investment thesis hinges on the successful clinical development and eventual commercialization of ATH434 and PBT2. Key value drivers include positive Phase II and Phase III clinical trial results for ATH434 in Parkinson's disease, and PBT2 in Alzheimer's disease. The company's small market capitalization of $0.03 billion reflects the early stage of its pipeline. Upcoming catalysts include the initiation of further clinical trials for ATH434. Potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding, which could dilute existing shareholders. The company's gross margin is 96.8%, but its profit margin is -380.7%.
Based on FMP financials and quantitative analysis
ATHE Key Highlights
- Lead drug candidate ATH434 has completed Phase I clinical trials for Parkinson's disease.
- PBT2 has completed Phase IIa clinical trials for Alzheimer's disease.
- Market capitalization of $0.03 billion reflects its early-stage biotechnology status.
- Gross margin of 96.8% indicates potential for high profitability upon successful commercialization.
- The company rebranded from Prana Biotechnology Limited to Alterity Therapeutics Limited in April 2019.
Who Are ATHE's Competitors?
What Are ATHE's Key Strengths?
- Novel drug candidates targeting unmet medical needs.
- Completed Phase I and Phase II clinical trials.
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
What Are ATHE's Weaknesses?
- Early-stage biotechnology company with limited financial resources.
- High risk of clinical trial failures.
- Dependence on external funding and partnerships.
- Small number of employees.
What Could Drive ATHE Stock Higher?
- Initiation of Phase II clinical trials for ATH434 in Parkinson's disease (estimated timeline: 2026-Q4).
- Publication of Phase I clinical trial results for ATH434 in a peer-reviewed journal (estimated timeline: 2026-Q3).
- Development of PBT2 for Alzheimer's disease, with potential for further clinical trials.
- Exploration of strategic partnerships with pharmaceutical companies for co-development and commercialization.
What Are the Key Risks for ATHE?
- Clinical trial failures for ATH434 or PBT2.
- Regulatory hurdles and delays in obtaining FDA approval.
- Need for additional funding, which could dilute existing shareholders.
- Competition from larger pharmaceutical companies with more resources.
- Dependence on key personnel and intellectual property.
What Are the Growth Opportunities for ATHE?
- Advancement of ATH434 in Parkinson's Disease: The global market for Parkinson's disease treatment is projected to reach $5.6 billion by 2028. Successful completion of Phase II and Phase III trials for ATH434 could lead to significant market share capture, providing a substantial growth opportunity for Alterity Therapeutics. The timeline for Phase II completion is estimated at 2-3 years, with potential commercialization within 5-7 years pending regulatory approval.
- Development of PBT2 for Alzheimer's Disease: The Alzheimer's disease treatment market is expected to reach $12.6 billion by 2028. Positive clinical trial results for PBT2 could position Alterity Therapeutics to address a critical unmet need in this market. Further clinical trials are planned, with potential for market entry in 5-7 years contingent on regulatory approvals.
- Expansion of Pipeline to Other Neurodegenerative Diseases: Alterity Therapeutics can leverage its expertise in neurodegenerative disease research to expand its pipeline beyond Parkinson's and Alzheimer's diseases. Targeting other conditions like Huntington's disease could open new market opportunities and diversify the company's revenue streams. This expansion could begin within the next 3-5 years.
- Strategic Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions could provide Alterity Therapeutics with access to additional funding, expertise, and resources. Collaborations can accelerate drug development timelines and increase the likelihood of successful commercialization. Potential partnerships could materialize within the next 1-2 years.
- Orphan Drug Designation and Accelerated Approval Pathways: Pursuing orphan drug designation for its drug candidates could provide Alterity Therapeutics with regulatory and financial incentives, including market exclusivity and expedited review processes. This strategy can shorten the time to market and enhance the commercial viability of its products. Applications for orphan drug designation are ongoing.
What Opportunities Does ATHE Have?
- Growing market for neurodegenerative disease treatments.
- Potential for orphan drug designation and accelerated approval pathways.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline to other neurological disorders.
What Threats Does ATHE Face?
- Competition from larger pharmaceutical companies with more resources.
- Regulatory hurdles and delays.
- Patent challenges and infringement.
- Economic downturn and reduced healthcare spending.
What Are ATHE's Competitive Advantages?
- Patented drug candidates provide exclusivity and protect against competition.
- Specialized expertise in neurodegenerative disease research and development.
- Clinical trial data demonstrating drug efficacy and safety.
- Orphan drug designation (if obtained) provides market exclusivity and regulatory benefits.
What Does ATHE Do?
Alterity Therapeutics Limited, founded in 1997 and headquartered in Melbourne, Australia, is a biotechnology company dedicated to researching and developing therapeutic drugs for neurodegenerative diseases. Originally incorporated as Prana Biotechnology Limited, the company rebranded to Alterity Therapeutics in April 2019 to reflect its evolving focus. The company's primary focus is on addressing unmet medical needs in diseases such as Alzheimer's, Huntington's, and Parkinson's disease. Their lead drug candidate, ATH434, has completed Phase I clinical trials for the treatment of Parkinson's disease. ATH434 is designed to inhibit the aggregation of α-synuclein, a protein implicated in Parkinson's disease pathology. Additionally, Alterity is developing PBT2, which has completed Phase IIa clinical trials for Alzheimer's disease. PBT2 aims to reduce amyloid plaques in the brain, a hallmark of Alzheimer's. Alterity Therapeutics operates primarily in Australia, focusing on early-stage drug development and clinical trials. The company's strategy involves identifying and developing novel therapies that target the underlying mechanisms of neurodegenerative diseases.
What Products and Services Does ATHE Offer?
- Researches and develops therapeutic drugs for neurodegenerative diseases.
- Focuses on treatments for Alzheimer's disease, Huntington's disease, and Parkinson's disease.
- Develops ATH434 for the treatment of Parkinson's disease.
- Develops PBT2 for the treatment of Alzheimer's disease.
- Conducts Phase I and Phase II clinical trials to evaluate drug efficacy and safety.
- Seeks to identify and develop novel therapies targeting the underlying mechanisms of neurodegenerative diseases.
How Does ATHE Make Money?
- Develops and patents novel therapeutic drugs.
- Conducts clinical trials to demonstrate drug efficacy and safety.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
What Industry Does ATHE Operate In?
Alterity Therapeutics operates within the biotechnology industry, which is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. The market for neurodegenerative disease treatments is substantial and growing, driven by an aging global population. Key competitors include companies like Annovis Bio (ANVS), Biohaven Pharmaceutical Holding Company (BTAI), and Denali Therapeutics (DNLI), all of which are developing therapies for similar indications. The industry is marked by intense competition and a high failure rate for drug candidates.
Who Are ATHE's Key Customers?
- Patients suffering from neurodegenerative diseases.
- Healthcare providers who prescribe and administer treatments.
- Pharmaceutical companies that may license or acquire Alterity's drugs.
- Research institutions and collaborators.
ATHE Financials
ATHE Latest News
-
Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA
benzinga · Mar 30, 2026
-
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
globenewswire.com · Mar 30, 2026
-
Alterity Therapeutics Conference: ATH434 Phase II MSA Data, FDA Talks Next, Phase III Set
defenseworld.net · Mar 26, 2026
-
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 69.4% in February
defenseworld.net · Mar 15, 2026
ATHE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATHE.
Price Targets
Consensus target: $11.00
ATHE MoonshotScore
What does this score mean?
The MoonshotScore rates ATHE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are ATHE's Competitors?
Latest News
Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alterity Therapeutics Conference: ATH434 Phase II MSA Data, FDA Talks Next, Phase III Set
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 69.4% in February
Leadership: David A. Stamler
CEO
David A. Stamler serves as the CEO of Alterity Therapeutics Limited. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on clinical development and regulatory affairs. He has held leadership positions at various companies, overseeing drug development programs and strategic initiatives. His expertise spans clinical trial design, data analysis, and regulatory submissions. He manages a team of 10 employees at Alterity Therapeutics.
Track Record: Under David Stamler's leadership, Alterity Therapeutics has advanced its lead drug candidate, ATH434, through Phase I clinical trials. He has also overseen the development of PBT2 and the company's strategic shift towards neurodegenerative diseases. Key milestones include securing funding for clinical trials and establishing partnerships with research institutions.
Alterity Therapeutics Limited ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For Alterity Therapeutics (ATHE), each ADR represents a specific number of ordinary shares of the company traded on its home market. This allows U.S. investors to invest in ATHE without dealing with foreign exchanges.
- Home Market Ticker: Australian Securities Exchange (ASX), Australia
- ADR Level: 2
- ADR Ratio: 1:1
ATHE Healthcare Stock FAQ
What does Alterity Therapeutics Limited do?
Alterity Therapeutics Limited is a biotechnology company focused on developing novel therapies for neurodegenerative diseases, including Parkinson's and Alzheimer's. Their lead drug candidate, ATH434, targets the aggregation of α-synuclein in Parkinson's disease, while PBT2 aims to reduce amyloid plaques in Alzheimer's. The company conducts clinical trials to evaluate the safety and efficacy of these drugs, seeking to address significant unmet medical needs in these disease areas. They operate primarily in Australia, with a global outlook for potential commercialization.
What do analysts say about ATHE stock?
Analyst coverage of Alterity Therapeutics (ATHE) is limited due to its small market capitalization and early-stage development. However, analysts generally focus on the potential of ATH434 and PBT2 to address unmet needs in Parkinson's and Alzheimer's diseases. Key valuation metrics include the potential market size for these therapies and the probability of successful clinical development and regulatory approval. Growth considerations center on the company's ability to secure funding and partnerships to advance its pipeline.
What are the main risks for ATHE?
The main risks for Alterity Therapeutics (ATHE) include the inherent uncertainty of clinical drug development, potential regulatory hurdles, and the need for additional funding. Clinical trial failures for ATH434 or PBT2 could significantly impact the company's value. Competition from larger pharmaceutical companies with more resources also poses a threat. Additionally, the company's small size and limited financial resources make it vulnerable to economic downturns and market volatility.
What are the key factors to evaluate for ATHE?
Alterity Therapeutics Limited (ATHE) currently holds an AI score of 58/100, indicating moderate score. Analysts target $11.00 (+196% from $3.71). Key strength: Novel drug candidates targeting unmet medical needs. Primary risk to monitor: Clinical trial failures for ATH434 or PBT2. This is not financial advice.
How frequently does ATHE data refresh on this page?
ATHE prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ATHE's recent stock price performance?
Recent price movement in Alterity Therapeutics Limited (ATHE) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $11.00 implies 196% upside from here. Notable catalyst: Novel drug candidates targeting unmet medical needs. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ATHE overvalued or undervalued right now?
Determining whether Alterity Therapeutics Limited (ATHE) is overvalued or undervalued requires examining multiple metrics. Analysts target $11.00 (+196% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ATHE?
Before investing in Alterity Therapeutics Limited (ATHE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.